MAPT and Alzheimer disease: Mattsson-Carlgren et al. 6 also used the Lilly p-tau217 MSD assay to stage AD but used those in the top 25% of neocortical PET tau as the high tau group as done in the Lilly Trailblazer-Alz 2 clinical trial1.